RUSHNET INC - RSHN STOCK NEWS

RushNet, Inc. (OTC PINK:RSHN) has partnered with Sciteck Diagnostics to adopt the AutoUA reagent system aimed at combating kidney disease and urinary tract infections (UTIs). This innovative system enhances patient care by detecting non-albumin proteinuria (NAP) earlier than traditional dipstick methods, which often leave many patients unaware of their kidney health. The AutoUA system can identify over 115 conditions and is recommended for high-risk groups, including patients with diabetes and hypertension. RushNet aims to improve shareholder value and reach $50 million in revenue.

RushNet, Inc. (OTC PINK:RSHN) has made significant strides towards its goals, including the spinout of heliosDX and a Tier 2 Regulation A filing. Key milestones achieved include a clean PCAOB audit, plans to issue dividend shares at a ratio of 650 RSHN to 1 heliosDX, and raising up to $20 million through discounted shares. The company aims to reach annual revenues of $50 million through acquisitions. Upcoming milestones include signing an agreement for a toxicology lab acquisition and obtaining SEC and FINRA approvals.

RushNet, Inc (OTC PINK:RSHN) announced plans for a dividend of heliosDX shares as part of its spinoff strategy. This move is designed to be free from dilution, maintaining the same number of outstanding RushNet shares. Following the completion of a PCAOB audit, the company aims to raise $20,000,000 via a Regulation A filing. Shareholders will receive one share of heliosDX for every 650 shares of RSHN owned. The anticipated submission date is within five business days, aligning with plans to file a Form 211 with FINRA.

Rushnet, Inc. (OTC PINK:RSHN) announces the completion of its PCAOB audit with a clean opinion from Somerset CPA's and Advisors, aimed at building investor confidence. The audit process has been lengthy, but management is optimistic about future business endeavors. The company reported healthy, growing revenues and plans to address cash flow concerns via restructuring agreements. Future steps include submitting for Regulation A, closing on acquisitions, aiming for $25 million in revenue, and uplisting to another stock exchange.

RushNet, Inc. (OTC PINK:RSHN) has announced a debt restructuring for the laboratory purchase of heliosDX. Originally set at $6 million, the current outstanding balance is approximately $4.4 million. The restructuring allows heliosDX to defer monthly payments of $64,000 until March 31, 2023, at a low interest rate of 2% above prime. This move aims to enhance profitability and cash flow, while avoiding adverse refinancing conditions. The management expresses gratitude towards former partners for understanding the long-term vision, which significantly benefits shareholders.

Rushnet, Inc. (OTC PINK:RSHN) has announced significant steps toward achieving its long-term goals, including a projected revenue target of $50 million within three years. The company has opted to withdraw its application for a reverse stock split, favoring alternative funding methods to mitigate shareholder concerns. This decision aims to facilitate the acquisition of a toxicology laboratory and enhance shareholder value. The company is moving forward with its plans for heliosDX and Grandeza Healthcare, focusing on expanding services and capabilities in healthcare diagnostics and billing.

RushNet, Inc (OTC PINK:RSHN) reports progress in its ongoing audit by Somerset CPAs and Advisors, nearing completion of the fifth week. A notable one-week field visit to Alpharetta, GA has been conducted, with potential follow-up visits planned for Jacksonville, Florida. The audit team indicates they are over the halfway mark but additional work remains. CEO Ashley Sweat expressed gratitude to Grandeza Healthcare and Whirley & Associates for their support. Updates will be provided as necessary via media pages and press releases.

RushNet, Inc. (OTC PINK:RSHN) has engaged Somerset CPAs and Advisors to audit its financials, including those of its subsidiaries, heliosDX and Grandeza Healthcare. The audit is set to begin immediately and is expected to take 30 to 60 days, with an upfront retainer of $100,000. CEO Ashley Sweat emphasized the importance of this engagement as a pivotal step for the companies and their shareholders. Completion of the audit will support previously outlined plans for growth in 2022. HeliosDX offers a range of laboratory services, while Grandeza Healthcare specializes in billing and consulting.

RushNet, Inc (OTC PINK:RSHN) has announced that its subsidiaries, heliosDX and Grandeza Healthcare, have exceeded their annual revenue forecasts. heliosDX achieved $6,000,000, a 39% increase from 2020, while Grandeza Healthcare surpassed its revised target of $1,600,000. RushNet’s consolidated forecast of $7,600,000 has also been exceeded. CEO Ashley Sweat indicated the company remains profitable despite significant marketing and expansion costs. RushNet is set to complete important audits to validate its financial standing.